Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business HighlightsGlobeNewsWire • 08/07/23
Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 StudyGlobeNewsWire • 08/07/23
Passage Bio to Present at Goldman Sachs 44th Annual Global Healthcare ConferenceGlobeNewsWire • 06/05/23
Passage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business HighlightsGlobeNewsWire • 05/11/23
Passage Bio to Present at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing SummitGlobeNewsWire • 04/17/23
Passage Bio to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease DaysGlobeNewsWire • 03/27/23
Passage Bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Recent Business HighlightsGlobeNewsWire • 03/06/23
Passage Bio to Report Fourth Quarter and Full-Year 2022 Financial Results on March 6, 2023GlobeNewsWire • 02/27/23
Passage Bio Presents Additional Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023GlobeNewsWire • 02/24/23
Passage Bio to Present Updated Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023GlobeNewsWire • 02/15/23
Passage Bio Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 StudyGlobeNewsWire • 12/14/22
Passage Bio Reports Third Quarter 2022 Financial Results and Provides Business UpdatesGlobeNewsWire • 11/10/22
Passage Bio to Report Third Quarter 2022 Financial Results on November 10, 2022GlobeNewsWire • 11/03/22
Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive OfficerGlobeNewsWire • 10/10/22
Newman Ferrara LLP Announces Corporate Governance Investigations of Passage Bio, Inc. (PASG)Business Wire • 09/07/22
Passage Bio Doses First Patient in Global Clinical Trial of PBFT02 Gene Therapy for Frontotemporal Dementia with Granulin MutationsGlobeNewsWire • 08/11/22